Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03463275 for Negative Symptoms of Schizophrenia
NCT00977522Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PF-03463275 in schizophrenia, sponsored by Pfizer. Started Nov 2009; status: terminated.
02
Drugs
PF-03463275
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00977522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00977522.